The Department of Health and Human Services has submitted a peptide “interim access policy” to the White House Office of Management and Budget for review, according to a government posting dated October 15, 2026. The move represents the first formal step in the Trump administration’s effort to create a legal pathway for compounding pharmacies to produce certain unapproved peptides while the FDA completes standard rulemaking.
The policy would allow 503A compounding pharmacies to temporarily produce certain popular peptides while formal federal rulemaking proceeds — a process that could take years. The filing does not disclose specifics about which peptides would be covered or what conditions would apply.
The OMB review stage is required before any federal regulation can take effect.
What happened
On October 15, 2026, HHS filed the interim access policy with the OMB, initiating the White House review process that precedes federal regulatory action. The submission was noted on a government website, though the document itself has not been publicly released in detail.
The policy is designed to allow specialty pharmacies operating under section 503A of the Federal Food, Drug, and Cosmetic Act to temporarily compound certain peptides that lack FDA approval. The filing does not specify which peptides would be covered, what conditions pharmacies would need to meet, or how long the interim access period would last.
Why it matters
The submission marks a significant development for several stakeholders:
- 503A compounding pharmacies, which could gain a temporary legal pathway to produce certain peptides.
- Telehealth companies offering peptide therapies, which face ongoing uncertainty over the legal status of compounded peptides.
- Consumers seeking legal alternatives to gray-market peptide products.
- FDA career staff, who have opposed the interim approach according to reporting on the matter.
Unapproved peptides such as BPC-157 have grown in popularity despite lacking FDA clearance. The interim policy, if finalized, could provide a regulated pathway for access while formal rulemaking — potentially spanning years — runs its course.
The OMB review is a mandatory procedural step. No interim access policy can take effect until that review is complete and any subsequent regulatory requirements are satisfied.
What to watch next
- The duration and outcome of the OMB review process.
- Whether the policy is opened to public comment before taking effect.
- Which specific peptides would be covered and what conditions would apply to compounding pharmacies.
- How FDA career staff respond to or interact with the interim framework.
- The timeline for both the interim policy and the eventual formal rulemaking process.
Sources
Industry information only. Not medical or legal advice.
